{"title":"Treatment Failures in Trigeminal Neuralgia Patients: An Institutional Audit","authors":"A. Abah, O. Emeka, G. Agbelusi","doi":"10.61172/ndj.v23i2.26","DOIUrl":null,"url":null,"abstract":"Background: Trigeminal Neuralgia (TN) is a frequent cause of paroxysmal facial pain and headaches in adults. It frequently presents in the fourth and fifth decade of life and affects the 5th cranial nerve. It is usually unilateral and does not disturb sleep. The gold standard drug is Carbamazepine (CBZ) and treatment failure to CBZ could be attributed to intake of drugs or food containing B group vitamins, patients' tolerance to the medication and the use of fake medication. The effectiveness of this drug has been reported but, there is dearth of literature that demonstrates causes of failure of CBZ in the treatment of trigeminal neuralgia.Objective: To determine the causes of treatment failure in Trigeminal neuralgia patients attending the Oral Medicine Clinic of Lagos University Teaching Hospital, Lagos, Nigeria.Materials and Methods: This was a retrospective study of cases of Trigeminal Neuralgia who presented at the Oral Medicine Clinic of the study institution between April 2009 and April 2012. Data were collated from patients' case notes and clinical records. The recorded parameters included patients' bio data, response to treatment and treatment failure. The results were analyzed using Statistical Package for Social Sciences for Windows(version 16).Results: A total number of 32 patients were diagnosed with Trigeminal neuralgia during this period. There were 22 (68.87%) females and 10 (31.2%) males; with female to male ratio of 2.2:1. Age range was 9 to 82years (mean 53.4±13.86). Carbamazepine was the principal drug prescribed. There was treatment failure associated with it due to the use of B group vitamins in 10 patients (31.5%); 5 (15.63%) from tolerance to the drug and 2(6.10%) from fake drugs. Twenty-seven (84.4%) patients went into remission when all the factors leading to failure were addressed; therefore the response rate was good.Conclusion: Carbamazepine was used as the primary drug in the treatment of trigeminal neuralgia and treatment failure was largely due to taking drinks and drugs containing B group vitamins. \n ","PeriodicalId":79241,"journal":{"name":"Nigerian Dental Journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nigerian Dental Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61172/ndj.v23i2.26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Trigeminal Neuralgia (TN) is a frequent cause of paroxysmal facial pain and headaches in adults. It frequently presents in the fourth and fifth decade of life and affects the 5th cranial nerve. It is usually unilateral and does not disturb sleep. The gold standard drug is Carbamazepine (CBZ) and treatment failure to CBZ could be attributed to intake of drugs or food containing B group vitamins, patients' tolerance to the medication and the use of fake medication. The effectiveness of this drug has been reported but, there is dearth of literature that demonstrates causes of failure of CBZ in the treatment of trigeminal neuralgia.Objective: To determine the causes of treatment failure in Trigeminal neuralgia patients attending the Oral Medicine Clinic of Lagos University Teaching Hospital, Lagos, Nigeria.Materials and Methods: This was a retrospective study of cases of Trigeminal Neuralgia who presented at the Oral Medicine Clinic of the study institution between April 2009 and April 2012. Data were collated from patients' case notes and clinical records. The recorded parameters included patients' bio data, response to treatment and treatment failure. The results were analyzed using Statistical Package for Social Sciences for Windows(version 16).Results: A total number of 32 patients were diagnosed with Trigeminal neuralgia during this period. There were 22 (68.87%) females and 10 (31.2%) males; with female to male ratio of 2.2:1. Age range was 9 to 82years (mean 53.4±13.86). Carbamazepine was the principal drug prescribed. There was treatment failure associated with it due to the use of B group vitamins in 10 patients (31.5%); 5 (15.63%) from tolerance to the drug and 2(6.10%) from fake drugs. Twenty-seven (84.4%) patients went into remission when all the factors leading to failure were addressed; therefore the response rate was good.Conclusion: Carbamazepine was used as the primary drug in the treatment of trigeminal neuralgia and treatment failure was largely due to taking drinks and drugs containing B group vitamins.
背景:三叉神经痛(TN)是成人阵发性面部疼痛和头痛的常见原因。它经常出现在生命的第四和第五十年,并影响第五脑神经。它通常是单侧的,不影响睡眠。金标准药物是卡马西平(Carbamazepine, CBZ), CBZ治疗失败的原因可能是摄入含有B族维生素的药物或食物、患者对药物的耐受性以及使用假药。该药物的有效性已被报道,但缺乏文献证明CBZ治疗三叉神经痛失败的原因。目的:探讨尼日利亚拉各斯大学教学医院口腔医学门诊三叉神经痛患者治疗失败的原因。材料和方法:本研究是对2009年4月至2012年4月在该研究机构口腔医学诊所就诊的三叉神经痛病例进行回顾性研究。数据整理自患者病例记录和临床记录。记录的参数包括患者的生物资料、治疗反应和治疗失败。使用Statistical Package for Social Sciences for Windows(version 16)对结果进行分析。结果:本组共32例患者诊断为三叉神经痛。其中女性22例(68.87%),男性10例(31.2%);男女比例为2.2:1。年龄范围9 ~ 82岁,平均53.4±13.86岁。卡马西平是主要的处方药物。10例(31.5%)患者因服用B族维生素导致治疗失败;5名(15.63%)来自药物耐受,2名(6.10%)来自假药。所有导致失败的因素得到解决后,27例(84.4%)患者进入缓解期;因此,反应率很好。结论:卡马西平是治疗三叉神经痛的主要药物,服用含B族维生素的饮料和药物是治疗失败的主要原因。